MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.lungcan.2026.109447

Медицинская библиотека · Lung cancer (Amsterdam, Netherlands) · 2026

Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.

Shiraishi Yoshimasa, Kishimoto Junji, Sugawara Shunichi, Mizutani Hideaki, Daga Haruko, Azuma Koichi, Matsumoto Hirotaka, Hataji Osamu, Nishino Kazumi, Mori Masahide, Shukuya Takehito, Saito Haruhiro, Tachihara Motoko, Tanaka Kaoru, Tsuya Asuka, Wakuda Kazushige, Yanagitani Noriko, Sakamoto Tomohiro, Baba Junko, Hata Akito, Okada Morihito, Kozuki Toshiyuki, Sato Yuki, Takahata Yuriko, Yamada Tadaaki, Yamamoto Nobuyuki, Nakagawa Kazuhiko, Okamoto Isamu

СтатьяРандомизированное исследованиеКлиническое исследование III фазыПеревод в очереди

Аннотация

BACKGROUND

The phase III APPLE trial evaluated the efficacy of adding bevacizumab to atezolizumab with carboplatin plus pemetrexed (APP) for individuals with advanced nonsquamous non-small cell lung cancer (NSCLC). We here report the long-term outcomes of this trial with 3.5 years of follow-up.

METHODS

Patients with advanced nonsquamous NSCLC were randomized 1:1 to receive APP or APP plus bevacizumab (APPB). Stratification factors were clinical stage, driver oncogenes, and PD-L1 expression. Endpoints included progression-free survival, overall survival (OS), and safety.

RESULTS

A total of 412 patients were enrolled; 1 patient was excluded from the intention-to-treat population. Of the remaining patients, 287 patients were classified as driver oncogene-negative and 124 as driver oncogene-positive. The updated median OS was 28.0 months in the APPB arm and 25.7 months in the APP arm, with a hazard ratio (HR) of 0.88 (95% confidence interval [CI], 0.70-1.10). For the driver oncogene-negative population, the median OS was 27.6 months in the APPB arm and 27.8 months in the APP arm (HR of 0.96 [95% CI, 0.73-1.27]), with the corresponding values for the driver oncogene-positive population being 28.0 and 20.8 months (HR of 0.71 [95% CI, 0.47-1.08]). Safety profiles did not change from earlier analysis.

CONCLUSIONS

The addition of bevacizumab to APP did not improve OS in patients with advanced nonsquamous NSCLC. In the driver oncogene-positive subgroup, favorable OS trend was observed in the bevacizumab arm, highlighting its potential as a treatment option for individuals who have failed molecular-targeted therapy.

Для цитирования: Shiraishi Yoshimasa, Kishimoto Junji, Sugawara Shunichi, Mizutani Hideaki, Daga Haruko, Azuma Koichi, Matsumoto Hirotaka, Hataji Osamu, Nishino Kazumi, Mori Masahide, Shukuya Takehito, Saito Haruhiro, Tachihara Motoko, Tanaka Kaoru, Tsuya Asuka, Wakuda Kazushige, Yanagitani Noriko, Sakamoto Tomohiro, Baba Junko, Hata Akito, Okada Morihito, Kozuki Toshiyuki, Sato Yuki, Takahata Yuriko, Yamada Tadaaki, Yamamoto Nobuyuki, Nakagawa Kazuhiko, Okamoto Isamu. Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.. Lung cancer (Amsterdam, Netherlands). 2026. DOI: 10.1016/j.lungcan.2026.109447.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.